393 related articles for article (PubMed ID: 18331612)
21. [Medullary thyroid carcinoma: prognostic factors].
Pelizzo MR; Busnardo B; Bernante P; Girelli ME; Nacamulli D; Toniato A; Piotto A
Minerva Chir; 1993 Nov; 48(21-22):1289-91. PubMed ID: 8152559
[TBL] [Abstract][Full Text] [Related]
22. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
23. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.
Kraeber-Bodéré F; Salaun PY; Oudoux A; Goldenberg DM; Chatal JF; Barbet J
Cancer; 2010 Feb; 116(4 Suppl):1118-25. PubMed ID: 20127952
[TBL] [Abstract][Full Text] [Related]
24. Medullary thyroid cancer: prognostic factors for survival and recurrence, recommendations for the extent of lymph node dissection and for surgical therapy in recurrent disease.
Pilaete K; Delaere P; Decallonne B; Bex M; Hauben E; Nuyts S; Clement P; Hermans R; Vander Poorten V
B-ENT; 2012; 8(2):113-21. PubMed ID: 22896930
[TBL] [Abstract][Full Text] [Related]
25. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.
Dottorini ME; Assi A; Sironi M; Sangalli G; Spreafico G; Colombo L
Cancer; 1996 Apr; 77(8):1556-65. PubMed ID: 8608543
[TBL] [Abstract][Full Text] [Related]
26. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
[TBL] [Abstract][Full Text] [Related]
27. Medullary thyroid carcinoma and biomarkers: past, present and future.
van Veelen W; de Groot JW; Acton DS; Hofstra RM; Höppener JW; Links TP; Lips CJ
J Intern Med; 2009 Jul; 266(1):126-40. PubMed ID: 19522831
[TBL] [Abstract][Full Text] [Related]
28. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
Mirallié E; Iacobone M; Sebag F; Henry JF
Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
[TBL] [Abstract][Full Text] [Related]
29. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.
Weber T; Schilling T; Frank-Raue K; Colombo-Benkmann M; Hinz U; Ziegler R; Klar E
Surgery; 2001 Dec; 130(6):1044-9. PubMed ID: 11742336
[TBL] [Abstract][Full Text] [Related]
30. Micromedullary thyroid cancer: how micro is truly micro?
Pillarisetty VG; Katz SC; Ghossein RA; Tuttle RM; Shaha AR
Ann Surg Oncol; 2009 Oct; 16(10):2875-81. PubMed ID: 19568813
[TBL] [Abstract][Full Text] [Related]
31. [The prognostic importance of calcitonin screening in familial medullary thyroid carcinoma].
Raue F; Geiger S; Buhr H; Frank-Raue K; Ziegler R
Dtsch Med Wochenschr; 1993 Jan; 118(3):49-52. PubMed ID: 8425457
[TBL] [Abstract][Full Text] [Related]
32. Hereditary medullary thyroid carcinoma in patients greater than 50 years old.
Quayle FJ; Benveniste R; DeBenedetti MK; Wells SA; Moley JF
Surgery; 2004 Dec; 136(6):1116-21. PubMed ID: 15657564
[TBL] [Abstract][Full Text] [Related]
33. Need for a revised staging consensus in medullary thyroid carcinoma.
Boostrom SY; Grant CS; Thompson GB; Farley DR; Richards ML; Hoskin TL; Hay ID
Arch Surg; 2009 Jul; 144(7):663-9. PubMed ID: 19620547
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous medullary and differentiated thyroid cancer: a population-level analysis of an increasingly common entity.
Wong RL; Kazaure HS; Roman SA; Sosa JA
Ann Surg Oncol; 2012 Aug; 19(8):2635-42. PubMed ID: 22526904
[TBL] [Abstract][Full Text] [Related]
35. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of familial medullary thyroid carcinoma].
Palestini N; Tagliabue M; Cestino L; Farnetti A; Rossetto R; Vendrame A
Minerva Chir; 2003 Dec; 58(6):801-9. PubMed ID: 14663408
[TBL] [Abstract][Full Text] [Related]
37. Should patients with medullary thyroid carcinoma undergo extensive lymph node (re)operation to improve long-term survival?
Brumsen C; Haak HR; Goslings BM; van de Velde CJ
Henry Ford Hosp Med J; 1992; 40(3-4):271-5. PubMed ID: 1483874
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group.
Bergholm U; Adami HO; Bergström R; Bäckdahl M; Akerström G
Acta Chir Scand; 1990 Jan; 156(1):37-46. PubMed ID: 2321439
[TBL] [Abstract][Full Text] [Related]
39. [Medullary carcinoma of the thyroid gland. Prognostic factors].
Gavilán I; Astorga R; Sasián S; Acosta D; Aguilar M; Leal A; Escobar L; Córdoba JA; Girón JA
Rev Clin Esp; 1996 Feb; 196(2):92-8. PubMed ID: 8685495
[TBL] [Abstract][Full Text] [Related]
40. Endoluminal resection for sessile neoplasia in the GI tract is associated with a low recurrence rate and a high 5-year survival rate.
Wang AY; Ahmad NA; Zaidman JS; Brensinger CM; Lewis JD; Long WB; Kochman ML; Ginsberg GG
Gastrointest Endosc; 2008 Jul; 68(1):160-9. PubMed ID: 18577483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
